Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the swap-2 study (switching anti platelet-2)

Journal of the American College of Cardiology

Volumn 63, Issue 15, 2014, Pages 1500-1509

  Angiolillo, Dominick J ^a   Curzen, Nicholas ^b   Gurbel, Paul ^c   Vaitkus, Paul ^d   Lipkin, Fred ^d   Li, Wei ^d   Jakubowski, Joseph A ^e   Zettler, Marjorie ^e   Effron, Mark B ^e   Trenk, Dietmar ^f  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^d DAIICHI SANKYO INC   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

drug interaction; pharmacodynamics; platelet function; prasugrel; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; PRASUGREL; TICAGRELOR;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; FEMALE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACODYNAMICS; PHASE 4 CLINICAL TRIAL; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION;

DRUG INTERACTION; PHARMACODYNAMICS; PLATELET FUNCTION; PRASUGREL; TICAGRELOR;

ADENOSINE; ADOLESCENT; ADULT; AGED; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902089776     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.11.032     Document Type: Article

References (25)

1. J.L. Anderson, C.D. Adams, and E.M. Antman et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e179 e347
2. G.N. Levine, E.R. Bates, and J.C. Blankenship et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
3. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
4. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
5. G.W. Stone, B. Witzenbichler, and G. Weisz et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
6. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
7. U.S. Tantry, L. Bonello, and D. Aradi et al. Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
8. J.L. Ferreiro, and D.J. Angiolillo New directions in antiplatelet therapy Circ Cardiovasc Interv 5 2012 433 445
9. S.D. Wiviott, E. Braunwald, and C.H. McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
10. L. Wallentin, R.C. Becker, and A. Budaj et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
11. N.A. Farid, A. Kurihara, and S.A. Wrighton Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans J Clin Pharmacol 50 2010 126 142
12. J.J. van Giezen, L. Nilsson, and P. Berntsson et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1555 1565
13. D.J. Angiolillo, J.J. Badimon, and J.F. Saucedo et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial Eur Heart J 32 2011 838 846
14. M.J. Price, S. Endemann, and R.R. Gollapudi et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
15. A. Malinin, A. Pokov, and M. Spergling et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study Thromb Res 119 2007 277 284
16. J.T. Brandt, C.D. Payne, and S.D. Wiviott et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66.e9 66.e16
17. T. Jernberg, C.D. Payne, and K.J. Winters et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
18. P.A. Gurbel, K.P. Bliden, and K. Butler et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
19. P.A. Gurbel, K.P. Bliden, and K. Butler et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
20. J.L. Ferreiro, M. Ueno, and A. Tello-Montoliu et al. Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy J Am Coll Cardiol Intv 6 2013 182 184
21. L. Bonello, M. Pansieri, and J. Mancini et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
22. D.J. Angiolillo, J.F. Saucedo, and R. Deraad et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 56 2010 1017 1023
23. J.F. Saucedo, D.J. Angiolillo, and R. DeRaad et al. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study Thromb Haemost 109 2013 347 355
24. D. Alexopoulos, A. Galati, and I. Xanthopoulou et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study J Am Coll Cardiol 60 2012 193 199
25. D. Alexopoulos, I. Xanthopoulou, and E. Mavronasiou et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes Diabetes Care 36 2013 2211 2216